



APRIL 2022

## KMAP GENERAL BULLETIN 22059

# COVID-19 Antiviral Coverage Update

Effective March 1, 2022, the following COVID-19 Oral antivirals will be covered by Emergency Use Authorization (EUA) until further notice:

- Paxlovid
- Molnupiravir

Excluding spenddown there will be no cost sharing at this time. Claims submitted with diagnosis code B9729 or U071 will be exempt from copay.

Pharmacies must bill with a cost of \$0.00 and a professional dispensing fee of \$10.50, and total claim reimbursement at this time will be no more than \$10.50.

**Note:** The effective date of the policy is March 1, 2022. The implementation of State policy by the KanCare managed care organizations (MCOs) may vary from the date noted in the Kansas Medical Assistance Program (KMAP) bulletins. The **KanCare Open Claims Resolution Log** on the KMAP [Bulletins](#) page documents the MCO system status for policy implementation and any associated reprocessing completion dates once the policy is implemented.

### KMAP

[Kansas Medical Assistance Program](#)

- [Bulletins](#)
- [Manuals](#)
- [Forms](#)

### Customer Service

- 1-800-933-6593
- 7:30 a.m. - 5:30 p.m.  
Monday - Friday

Gainwell Technologies is the fiscal agent for KMAP